Sickle Cell Disease is Associated with Increased Morbidity, Resource Utilization, and Readmissions after Common Abdominal Surgeries: A Multistate Analysis, 2007–2014

Brumm, John; White, Robert S.; Arroyo, Noelle S.; Gaber-Baylis, Licia K.; Gupta, Soham; Turnbull, Zachary A.; Mehta, Neel

doi:10.1016/j.jnma.2020.01.001

Cited by 5 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk of death is highest in early childhood, with stroke and infections being common causes [34,35]. Morbidity rates are also very high, with most patients experiencing frequent pain crises, chronic anemia, recurrent infections, and organ damage early in life [36,37]. Over half of the patients have lung, liver, kidney, or heart impairment by age 18 [37,38].…”

Section: Epidemiology and Morbidity Of Scdmentioning

confidence: 99%

“…Morbidity rates are also very high, with most patients experiencing frequent pain crises, chronic anemia, recurrent infections, and organ damage early in life [36,37]. Over half of the patients have lung, liver, kidney, or heart impairment by age 18 [37,38]. Stroke is a significant complication, affecting 11% of patients by age 20 [4,39].…”

Section: Epidemiology and Morbidity Of Scdmentioning

confidence: 99%

See 1 more Smart Citation

Overview of the Association Between the Pathophysiology, Types, and Management of Sickle Cell Disease and Stroke

Hakami,

Alhazmi,

Busayli

et al. 2023

Cureus

View full text Add to dashboard Cite

Sickle cell disease (SCD) is a genetic blood disorder that affects hemoglobin and increases stroke risk, particularly in childhood. This review examines the pathophysiological association between SCD and stroke, the classification of stroke types, risk factors, diagnosis, management, prevention, and prognosis. A comprehensive literature search was conducted via PubMed, Scopus, and Cochrane databases. Relevant studies on SCD and stroke pathophysiology, classification, epidemiology, diagnosis, treatment, and prevention were identified.Sickle cell disease causes red blood cells to become rigid and sickle-shaped, obstructing blood vessels. Recurrent sickling alters cerebral blood flow and damages vessel walls, often leading to ischemic or hemorrhagic strokes (HS). These occur most frequently in childhood, with ischemic strokes (IS) being more common. Key risk factors include a prior transient ischemic attack (TIA), low hemoglobin, and a high leukocyte count. Neuroimaging is essential for diagnosis and determining stroke type. Primary prevention centers on blood transfusions and hydroxyurea for those at high risk. Acute treatment involves promptly restoring blood flow and managing complications. However, significant knowledge gaps remain regarding stroke mechanisms, optimizing screening protocols, and improving long-term outcomes. This review synthesizes current evidence on SCD and stroke to highlight opportunities for further research and standardizing care protocols across institutions. Ultimately, a holistic perspective is critical for mitigating the high risk of debilitating strokes in this vulnerable patient population.

show abstract

Section: Epidemiology and Morbidity Of Scdmentioning

confidence: 99%

Section: Epidemiology and Morbidity Of Scdmentioning

confidence: 99%

Overview of the Association Between the Pathophysiology, Types, and Management of Sickle Cell Disease and Stroke

Hakami,

Alhazmi,

Busayli

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…There was an equal split in the pattern for reported units of analysis, with per patient (47%) [22-24, 29, 31, 32, 35, 42, 43, 47-49, 54-56, 58-61] and per hospital admission (50%) [25-28, 30, 33, 34, 36-42, 44, 46, 50, 51, 53, 57] as the most frequently reported units. Inpatient costs [22,23,[25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61] were the most frequently reported cost component, followed by outpatient [23, 24, 31, 32, 35, 39, 42-44, 47, 48, 51, 54, 56, 58-61], pharmacy [22-24, 31, 32, 35, 42, 43, 47, 48, 56, 58-61], and ED costs [22,23,29,31,35,…”

Section: Study Demographicsmentioning

confidence: 99%

“…Mean differences in general inpatient costs between SCD and non-SCD individuals ranged from $6636 to $63,436 per patient annually (Table 3). With respect to specific admission procedures, SCD individuals experienced a higher economic burden than non-SCD individuals during post-partum recovery [26], appendectomy, cholecystectomy, and hysterectomy [27]. In a study that explored cholecystectomy, authors reported that during admission for either an elective or acute procedure, the incremental costs due to SCD were $406 and $6510, respectively [28].…”

Section: Sickle Cell Disease (Scd) Versus Non-scdmentioning

confidence: 99%

Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis

Baldwin

Jiao

Basu

et al. 2022

PharmacoEconomics Open

View full text Add to dashboard Cite

Background Sickle cell disease (SCD) is a complex genetic disorder that manifests in infancy and progresses throughout life in the form of acute and chronic complications. As the upfront costs of potentially curative, genetic therapies will likely be high, an assessment and comprehensive characterization of the medical and non-medical cost burden will inform future decision making. Objective We sought to systematically summarize the existing literature surrounding SCD medical and non-medical costs. Methods We searched MEDLINE and EMBASE (2008-2020) and identified US-based studies that detailed medical or non-medical costs. Eligible studies provided empirical estimates about any aspect of cost or SCD individuals of all ages and their caregivers. Study quality was assessed using the Newcastle-Ottawa Scale, and costs were adjusted to 2019 US$. Results Search queries returned 479 studies, with 342 from medical burden searches and 137 from non-medical burden searches, respectively. Herein, we report the results of the 40 studies that contained relevant cost information: 39 detailed medical costs and 1 detailed non-medical costs. Costs were higher for SCD patients when compared with non-SCD individuals

show abstract

“…Findings from empirical studies reveal that readmission is the highest in SCD patients who live in socio-economically deprived areas, where access to care is limited to the population most in need [20][21][22][23][24]. Among other factors contributing to increased SCD readmissions, particularly among patients from lower socio-economic status is the number of comorbidities.…”

Section: Introductionmentioning

confidence: 99%

Predictors of hospital readmissions in adult patients with sickle cell disease

Santiago

2023

Am J Blood Res

View full text Add to dashboard Cite

Background: Sickle cell disease (SCD) is the most common inherited blood disorder, affecting primarily Black and Hispanic individuals. In 2016, 30-day readmissions incurred 95,445 extra days of hospitalization, $152 million in total hospitalization costs, and $609 million in total hospitalization charges. Objectives: 1) To estimate hospital readmissions within 30 days among patients with SCD in the State of California. 2) Identify the factors associated with readmission within 30 days for SCD patients in California. Methods: We conducted a retrospective observational study of adult SCD patients hospitalized in California between 2005 and 2014. Descriptive statistics and logistic regression models were used to examine significant differences in patient characteristics and their association with hospital readmissions. Results: From 2,728 individual index admissions, 70% presented with single admission, 10% experienced one readmission, and 20% experienced ≥ two readmissions within 30 days. Significant predictors associated with zero vs. one readmission were male gender (OR=1.

show abstract

Sickle Cell Disease is Associated with Increased Morbidity, Resource Utilization, and Readmissions after Common Abdominal Surgeries: A Multistate Analysis, 2007–2014

Cited by 5 publications

References 35 publications

Overview of the Association Between the Pathophysiology, Types, and Management of Sickle Cell Disease and Stroke

Overview of the Association Between the Pathophysiology, Types, and Management of Sickle Cell Disease and Stroke

Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis

Predictors of hospital readmissions in adult patients with sickle cell disease

Contact Info

Product

Resources

About